REVOLINC project

Recently, we hypothesized that shifting the vision of the sterile male from a sexual competitor only to a specific transporter of active biocides to the targeted female might boost the impact of the sterile insect technique (SIT). In Revolinc, we investigate this concept using two biocides: Pyriproxifen and a Densovirus against the Tiger mosquito (Aedes albopictus). Pyriproxifen will also be tested against tsetse and fruit flies.

We are testing the technology both in the laboratory and at an operational scale and model the relative impacts of SIT and boosted-SIT on the dynamics of the targeted population. Moreover, we will compare the evolutionary response of the target population to these different control pressures (multiple lethal mutations, multiple lethal mutations + biocides), for different biocides and demographic strategies. This will generate breakthrough knowledge on the transmission of biocides and pathogens in insects and the sustainability of genetic control, provide a new control technique, and improve the cost-effectiveness of SIT.

EFSA recently prohibited 75% of insecticides to account for their toxicity and ecotoxicity. Moreover, the spread of insecticide resistance and invasion of Europe by new tropical vectors and pests require the development of alternative biological techniques.